

Priya Kumthekar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/441748/publications.pdf>

Version: 2024-02-01

109
papers

2,505
citations

257450

24
h-index

223800

46
g-index

122
all docs

122
docs citations

122
times ranked

3494
citing authors

#	ARTICLE	IF	CITATIONS
1	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1537-1570.	4.9	253
2	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Science Translational Medicine, 2019, 11, .	12.4	170
3	Mutant IDH1 and seizures in patients with glioma. Neurology, 2017, 88, 1805-1813.	1.1	167
4	A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma. Science Translational Medicine, 2021, 13, .	12.4	136
5	Mutant IDH1 and thrombosis in gliomas. Acta Neuropathologica, 2016, 132, 917-930.	7.7	130
6	ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clinical Cancer Research, 2020, 26, 2789-2799.	7.0	130
7	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncology, The, 2021, 22, 1103-1114.	10.7	91
8	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro-Oncology, 2019, 21, 106-114.	1.2	84
9	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology, 2017, 19, now257.	1.2	80
10	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2021, 325, 1277.	7.4	63
11	Low-Grade Glioma. Cancer Treatment and Research, 2015, 163, 75-87.	0.5	61
12	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-Oncology, 2018, 20, 838-847.	1.2	60
13	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of Clinical Oncology, 2021, 39, 2667-2675.	1.6	58
14	Pleomorphic xanthoastrocytoma: a brief review. CNS Oncology, 2019, 8, CNS39.	3.0	53
15	Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. Journal of Neuro-Oncology, 2013, 112, 247-255.	2.9	52
16	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clinical Cancer Research, 2020, 26, 5232-5245.	7.0	52
17	Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal of Neuro-Oncology, 2020, 148, 599-606.	2.9	50
18	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro-Oncology, 2020, 22, 470-479.	1.2	49

#	ARTICLE	IF	CITATIONS
19	State-of-the-art considerations in small cell lung cancer brain metastases. <i>Oncotarget</i> , 2017, 8, 71223-71233.	1.8	47
20	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	1.2	39
21	Leptomeningeal metastasis from solid tumors. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116706.	0.6	34
22	<i>De novo</i> purine biosynthesis is a major driver of chemoresistance in glioblastoma. <i>Brain</i> , 2021, 144, 1230-1246.	7.6	30
23	Glioblastoma as an age-related neurological disorder in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vtab125.	0.7	30
24	A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3012-3012.	1.6	30
25	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. <i>Molecular Cancer Research</i> , 2018, 16, 32-46.	3.4	29
26	Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4005-4005.	1.6	29
27	Comparison of Biomarker Assays for <i>EGFR</i> : Implications for Precision Medicine in Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 3259-3265.	7.0	24
28	Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden. <i>Neuro-Oncology Practice</i> , 2014, 1, 47-54.	1.6	23
29	Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 917-925.	2.5	23
30	A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 133, 589-594.	2.9	22
31	Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma. <i>Future Oncology</i> , 2018, 14, 391-407.	2.4	22
32	Optimal Management of Corticosteroids in Patients with Intracranial Malignancies. <i>Current Treatment Options in Oncology</i> , 2020, 21, 77.	3.0	22
33	ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi29-vi29.	1.2	21
34	Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients. <i>BMC Cancer</i> , 2020, 20, 447.	2.6	20
35	Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2000-2000.	1.6	18
36	Gene Delivery in Neuro-Oncology. <i>Current Oncology Reports</i> , 2017, 19, 69.	4.0	18

#	ARTICLE	IF	CITATIONS
37	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	1.2	18
38	Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2502-2502.	1.6	17
39	Improving vaccine efficacy against malignant glioma. <i>Oncolmmunology</i> , 2016, 5, e1196311.	4.6	16
40	ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2004-2004.	1.6	16
41	ATIM-33. INTERIM RESULTS OF A PHASE II MULTI-CENTER STUDY OF ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). <i>Neuro-Oncology</i> , 2019, 21, vi8-vi9.	1.2	13
42	Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases. <i>Scientific Reports</i> , 2019, 9, 17792.	3.3	13
43	Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2058-2058.	1.6	11
44	Leptomeningeal metastases: the future is now. <i>Journal of Neuro-Oncology</i> , 2022, 156, 443-452.	2.9	11
45	Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. <i>Future Oncology</i> , 2016, 12, 1045-1058.	2.4	10
46	Advances in the diagnosis, evaluation, and management of leptomeningeal disease. <i>Neuro-Oncology Advances</i> , 2021, 3, v86-v95.	0.7	10
47	Financial burden experienced by patients undergoing treatment for malignant gliomas. <i>Neuro-Oncology Practice</i> , 2014, 1, 71-76.	1.6	9
48	CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi58-vi58.	1.2	9
49	LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY. <i>Neuro-Oncology Advances</i> , 2019, 1, i6-i6.	0.7	9
50	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2003-2003.	1.6	9
51	Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2044-2044.	1.6	8
52	MNGO-04PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH SURGERY AND RADIATION REFRACTORY PROGRESSIVE MENINGIOMA. <i>Neuro-Oncology</i> , 2015, 17, v130.4-v130.	1.2	7
53	Quality of Life of Family Caregivers of Patients With Cancer in KorËse, Albania. <i>Journal of Palliative Care</i> , 2019, 34, 118-125.	1.0	7
54	Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2⁺ breast leptomeningeal disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1099-TPS1099.	1.6	7

#	ARTICLE	IF	CITATIONS
55	Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies. CNS Drugs, 2022, 36, 167-179.	5.9	6
56	Abstract P1-18-03: Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study. , 2020, , .		5
57	A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastasis.. Journal of Clinical Oncology, 2017, 35, TPS1110-TPS1110.	1.6	5
58	A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT).. Journal of Clinical Oncology, 2019, 37, 2070-2070.	1.6	5
59	Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.. Journal of Clinical Oncology, 2021, 39, 2024-2024.	1.6	4
60	Alliance A071701: Genomically guided treatment trial in brain metastases.. Journal of Clinical Oncology, 2020, 38, TPS2573-TPS2573.	1.6	4
61	Advances in the Diagnosis and Treatment of Leptomeningeal Disease. Current Neurology and Neuroscience Reports, 2022, 22, 413-425.	4.2	4
62	NIMG-21. SEX DIFFERENCES IN EXTREME SURVIVORSHIP AMONG PRIMARY GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2018, 20, vi180-vi180.	1.2	3
63	ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 655-661.	1.3	3
64	A broad perspective on evaluating bias in the neuro-oncology workplace. Neuro-Oncology, 2021, 23, 498-499.	1.2	3
65	Prognosis of older patients with low-grade glioma: A retrospective study. Integrative Cancer Science and Therapeutics, 2017, 4, .	0.1	3
66	Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.. Journal of Clinical Oncology, 2017, 35, 3075-3075.	1.6	3
67	CTIM-12. A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHwt GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi51-vi52.	1.2	3
68	Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases. Cancers, 2022, 14, 17.	3.7	3
69	QOLP-25. QUALITY OF LIFE FOLLOWING RE-IRRADIATION FOR RECURRENT HIGH GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi220-vi220.	1.2	2
70	QOLP-20. IMPACT OF GLIOBLASTOMA ON PATIENT-REPORTED SYMPTOM BURDEN AND PHYSICAL ACTIVITY ASSESSED BY CONVENTIONAL INSTRUMENTS AND A NOVEL DEVICEâ€“BASED TECHNOLOGY. Neuro-Oncology, 2019, 21, vi201-vi202.	1.2	2
71	Factors affecting time to brain metastases for stage 2 and 3 breast cancer patients: A large single-institutional analysis with potential screening implications. Neuro-Oncology Advances, 2021, 3, vdab009.	0.7	2
72	Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.. Journal of Clinical Oncology, 2016, 34, 2052-2052.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.. Journal of Clinical Oncology, 2018, 36, 3075-3075.	1.6	2
74	Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.. Journal of Clinical Oncology, 2020, 38, 4003-4003.	1.6	2
75	ATIM-10. PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi19-vi19.	1.2	1
76	ATIM-02. TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA IN A PHASE 2 STUDY. Neuro-Oncology, 2018, 20, vi1-vi1.	1.2	1
77	ATIM-06. PHASE 2 TRIAL OF SL-701 + BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA (GBM) MEETS PRIMARY ENDPOINT OF OS-12, WITH PRELIMINARY CORRELATION BETWEEN LONG-TERM SURVIVAL AND TARGET-SPECIFIC CD8+ T CELL IMMUNE RESPONSE. Neuro-Oncology, 2018, 20, vi2-vi2.	1.2	1
78	QOLP-11. QUALITY OF LIFE IN HIGH-GRADE GLIOMA PATIENTS ON A PHASE I VIROTHERAPY STUDY. Neuro-Oncology, 2018, 20, vi216-vi216.	1.2	1
79	ACTR-40. PHASE 2 SAFETY AND EFFICACY OF AR-67 (7-T-BUTYLDIMETHYLSILTYL-10-HYDROXYCAMPTOTHECIN) IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) OR GLIOSARCOMA. Neuro-Oncology, 2019, 21, vi22-vi22.	1.2	1
80	NIMG-58. SEX DIFFERENCES IN CONTRAST-ENHANCING GLIOMAS AT PRESENTATION. Neuro-Oncology, 2019, 21, vi174-vi174.	1.2	1
81	HOLT-11. EXTENSIVE BRAINSTEM INFILTRATION, NOT MASS EFFECT, IS A COMMON FEATURE OF END-STAGE CEREBRAL GLIOBLASTOMAS. Neuro-Oncology, 2019, 21, vi114-vi114.	1.2	1
82	INNV-19. SURVEYING BIAS IN NEURO-ONCOLOGY AND SOCIETY FOR NEURO ONCOLOGY (SNO) MEMBERS: GENDER AND BEYOND. Neuro-Oncology, 2019, 21, vi134-vi134.	1.2	1
83	In pursuit of a perpetually burning flame: preventing burnout in neuro-oncology. Neuro-Oncology, 2020, 22, 750-751.	1.2	1
84	Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.. Journal of Clinical Oncology, 2021, 39, 361-361.	1.6	1
85	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. Neuro-Oncology, 2021, 23, vi126-vi127.	1.2	1
86	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 2022, 4, vdab186.	0.7	1
87	CMET-16. A PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH RECURRENT SOLID TUMOR BRAIN METASTASES WHO HAVE PROGRESSED FOLLOWING WHOLE BRAIN RADIATION THERAPY (WBRT): FINAL RESULTS. Neuro-Oncology, 2019, 21, vi54-vi54.	1.2	0
88	CMET-11. RESPONSE TO STEREOTACTIC RADIOSURGERY FOR MULTIPLE BRAIN METASTASES BASED ON HISTOLOGY-SPECIFIC SUBTYPE STATUS. Neuro-Oncology, 2019, 21, vi53-vi53.	1.2	0
89	QOLP-31. ASSESSING THE IMPACT OF GLIOBLASTOMA ON WORK PRODUCTIVITY IN PATIENTS AND THEIR CAREGIVERS. Neuro-Oncology, 2019, 21, vi204-vi204.	1.2	0
90	Stalking the Diagnosis. New England Journal of Medicine, 2021, 384, 1262-1267.	27.0	0

#	ARTICLE	IF	CITATIONS
91	An investigation into the impact of next generation sequencing on the use of targeted treatments in glioblastoma.. Journal of Clinical Oncology, 2021, 39, 2035-2035.	1.6	0
92	A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2071-TPS2071.	1.6	0
93	American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors. Future Oncology, 2021, 17, 4425-4429.	2.4	0
94	A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, TPS1100-TPS1100.	1.6	0
95	Abstract CT081: Tumor treating fields in combination with Bevacizumab in recurrent or progressive meningioma in a phase II study. , 2018, , .		0
96	Post-operative disposition and readmission rates in repeat resections for glioblastoma.. Journal of Clinical Oncology, 2020, 38, e14543-e14543.	1.6	0
97	BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology, 2021, 23, vi10-vi10.	1.2	0
98	INNV-13. UNDERSTANDING FACTORS THAT INFLUENCE THE DECISION OF ACCEPTING TUMOR TREATING FIELDS (TTF) THERAPY. Neuro-Oncology, 2021, 23, vi107-vi108.	1.2	0
99	CTIM-11. PHASE 2 STUDY OF SL-701, A NOVEL IMMUNOTHERAPY, IN ADULTS WITH RECURRENT GBM: A HIGH PARAMETER FLOW CYTOMETRY ANALYSIS OF CD8+ T CELLS AND POTENTIAL IMPLICATIONS FOR PATIENT ENRICHMENT STRATEGIES. Neuro-Oncology, 2021, 23, vi51-vi51.	1.2	0
100	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. Neuro-Oncology, 2021, 23, vi72-vi72.	1.2	0
101	CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi62-vi63.	1.2	0
102	QOLP-02. PATIENT-REPORTED OUTCOMES FOLLOWING PERTUZUMAB PLUS HIGH-DOSE TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) AND CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION POST-RADIOTHERAPY. Neuro-Oncology, 2020, 22, ii174-ii175.	1.2	0
103	IMMU-44. PRE-DIAGNOSTIC EOSINOPHIL LEVEL AND GLIOBLASTOMA DEVELOPMENT IN PATIENTS WITH AND WITHOUT ATOPIC DISEASE. Neuro-Oncology, 2020, 22, ii114-ii114.	1.2	0
104	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. Neuro-Oncology, 2021, 23, vi72-vi72.	1.2	0
105	The PROTECT Study: A phase II, open-label trial of prophylactic skin toxicity therapy with clindamycin and triamcinolone in patients with glioblastoma treated with tumor-treating fields.. Journal of Clinical Oncology, 2022, 40, TPS2084-TPS2084.	1.6	0
106	Investigating the impact of NGS data availability on clinical decision-making in brain cancer.. Journal of Clinical Oncology, 2022, 40, 2032-2032.	1.6	0
107	Preclinical modeling in leptomeningeal disease: Starting at the foundation to tackle a difficult disease. Neuro-Oncology, 0, , .	1.2	0
108	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.. Journal of Clinical Oncology, 2022, 40, 2026-2026.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Digital monitoring and assessments in patients with glioblastoma.. Journal of Clinical Oncology, 2022, 40, 2045-2045.	1.6	0